HomeCompareBHLIF vs PFE

BHLIF vs PFE: Dividend Comparison 2026

BHLIF yields 18181.82% · PFE yields 6.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 BHLIF wins by $20382968138483965952.00M in total portfolio value
10 years
BHLIF
BHLIF
● Live price
18181.82%
Share price
$0.01
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$20382968138483965952.00M
Annual income
$20,164,798,479,641,134,000,000,000.00
Full BHLIF calculator →
PFE
Pfizer Inc.
● Live price
6.13%
Share price
$28.08
Annual div
$1.72
5Y div CAGR
13.2%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$49.6K
Annual income
$26,258.71
Full PFE calculator →

Portfolio growth — BHLIF vs PFE

📍 BHLIF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodBHLIFPFE
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, BHLIF + PFE cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
BHLIF pays
PFE pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

BHLIF
Annual income on $10K today (after 15% tax)
$1,545,454.55/yr
After 10yr DRIP, annual income (after tax)
$17,140,078,707,694,964,000,000,000.00/yr
PFE
Annual income on $10K today (after 15% tax)
$520.66/yr
After 10yr DRIP, annual income (after tax)
$22,319.90/yr
At 15% tax rate, BHLIF beats the other by $17,140,078,707,694,964,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of BHLIF + PFE for your $10,000?

BHLIF: 50%PFE: 50%
100% PFE50/50100% BHLIF
Portfolio after 10yr
$10191484069241982976.00M
Annual income
$10,082,399,239,820,567,000,000,000.00/yr
Blended yield
98.93%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PFE right now

BHLIF
No analyst data
Altman Z
19.9
Piotroski
4/9
PFE
Analyst Ratings
16
Buy
22
Hold
1
Sell
Consensus: Hold
Price Target
$27.50
-2.1% upside vs current
Range: $24.00 — $35.00
Altman Z
2.0
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

BHLIF buys
0
PFE buys
0
No recent congressional trades found for BHLIF or PFE in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricBHLIFPFE
Forward yield18181.82%6.13%
Annual dividend / share$2.00$1.72
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%13.2%
Portfolio after 10y$20382968138483965952.00M$49.6K
Annual income after 10y$20,164,798,479,641,134,000,000,000.00$26,258.71
Total dividends collected$20368560651224936448.00M$58.3K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: BHLIF vs PFE ($10,000, DRIP)

YearBHLIF PortfolioBHLIF Income/yrPFE PortfolioPFE Income/yrGap
1← crossover$1,828,882$1,818,181.82$9,153$693.39+$1.82MBHLIF
2$312,726,966$310,770,062.56$8,593$849.25+$312.72MBHLIF
3$49,997,862,140$49,663,244,286.24$8,336$1,066.78+$49997.85MBHLIF
4$7,474,070,205,933$7,420,572,493,443.65$8,437$1,384.80+$7474070.20MBHLIF
5$1,044,712,232,322,833$1,036,714,977,202,484.10$9,013$1,875.40+$1044712232.31MBHLIF
6$136,547,911,758,351,100$135,430,069,669,765,680.00$10,306$2,680.72+$136547911758.34MBHLIF
7$16,689,313,388,956,088,000$16,543,207,123,374,653,000.00$12,820$4,101.38+$16689313388956.08MBHLIF
8$1,907,542,220,817,720,100,000$1,889,684,655,491,537,200,000.00$17,673$6,826.70+$1907542220817720.25MBHLIF
9$203,896,877,423,206,970,000,000$201,855,807,246,932,000,000,000.00$27,543$12,591.86+$203896877423206976.00MBHLIF
10$20,382,968,138,483,967,000,000,000$20,164,798,479,641,134,000,000,000.00$49,560$26,258.71+$20382968138483965952.00MBHLIF

BHLIF vs PFE: Complete Analysis 2026

BHLIFStock

Bradda Head Lithium Limited, through its subsidiaries, engages in the exploration, development, and mining of lithium mining projects in the United States. It holds 100% interests in Basin East located in central western Arizona, which covers an area of approximately 3.78 square kilometers (km2); Basin West consists of 65 placer mining and 72 lode claims that cover an area of approximately 6.02 km2 situated in central western Arizona; and Wikieup project comprises 120 federal placer mining claims and 225 lode claims, which covers an area of approximately 27.87 km2 located in the Mohave County, Arizona. The company also owns Wilson Salt Flat, a lithium brine project located in Nye County, Nevada; the Eureka lithium brine project covering an area of 11.8km2; and the San Domingo project consists of 68 BLM placer claims, which covers an area of approximately 13.5 km2 located in the Maricopa and Yavapai counties, Arizona. The company was formerly known as Bradda Head Holdings Limited and changed its name to Bradda Head Lithium Limited in September 2021. Bradda Head Lithium Limited is headquartered in Douglas, Isle of Man.

Full BHLIF Calculator →

PFEHealthcare

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Full PFE Calculator →
📬

Get this BHLIF vs PFE comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

BHLIF vs SCHDBHLIF vs JEPIBHLIF vs OBHLIF vs KOBHLIF vs MAINBHLIF vs JNJBHLIF vs MRKBHLIF vs ABBV

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.